SAB Biotherapeutics Future Growth
Future criteria checks 0/6
SAB Biotherapeutics's revenue and earnings are forecast to decline at 100% and 14.1% per annum respectively while EPS is expected to grow by 4% per annum.
Key information
-14.1%
Earnings growth rate
4.0%
EPS growth rate
| Biotechs earnings growth | 24.0% |
| Revenue growth rate | -100.0% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 16 Apr 2024 |
Recent future growth updates
Recent updates
Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified
Apr 17
Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week
Jan 20Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues
Nov 19Earnings Beat: SAB Biotherapeutics, Inc. (NASDAQ:SABS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Nov 18SAB Bio rises as H1N1 influenza and COVID-19 treatments show efficacy in trial
Sep 28What Does The Future Hold For SAB Biotherapeutics, Inc. (NASDAQ:SABS)? These Analysts Have Been Cutting Their Estimates
Aug 12SAB Biotherapeutics GAAP EPS of -$0.11 beats by $0.03
Aug 10Downgrade: Here's How Analysts See SAB Biotherapeutics, Inc. (NASDAQ:SABS) Performing In The Near Term
Apr 06SAB Biotherapeutics: Advancing A New Class Of Immunotherapies Leveraging Polyclonal Antibodies
Dec 02Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -63 | N/A | -56 | 1 |
| 12/31/2025 | N/A | -57 | N/A | -51 | 1 |
| 12/31/2024 | N/A | -45 | N/A | -38 | 2 |
| 12/31/2023 | 2 | -42 | -25 | -25 | N/A |
| 9/30/2023 | 4 | -27 | -13 | -13 | N/A |
| 6/30/2023 | 6 | -29 | -16 | -16 | N/A |
| 3/31/2023 | 13 | -27 | -16 | -16 | N/A |
| 12/31/2022 | 24 | -19 | -26 | -23 | N/A |
| 9/30/2022 | 33 | -22 | -31 | -27 | N/A |
| 6/30/2022 | 44 | -19 | -23 | -15 | N/A |
| 3/31/2022 | 56 | -18 | -27 | -17 | N/A |
| 12/31/2021 | 61 | -17 | -9 | 2 | N/A |
| 9/30/2021 | 76 | 7 | -3 | 11 | N/A |
| 6/30/2021 | 78 | 17 | -4 | 13 | N/A |
| 3/31/2021 | 66 | 21 | 6 | 19 | N/A |
| 12/31/2020 | 55 | 20 | -3 | 10 | N/A |
| 12/31/2019 | 3 | -9 | -10 | -9 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SABS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SABS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SABS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SABS is forecast to have no revenue next year.
High Growth Revenue: SABS is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SABS's Return on Equity is forecast to be high in 3 years time